Choong-Yong Kim

Suggest Changes
Learn More
CKD-501 (i.e., lobeglitazone), a potent agonist for both PPARalpha/gamma, is a new drug that has potential clinical applications in the management of type-2 diabetes. The objective of this study was(More)